摘要
探讨舒芬太尼皮下自控镇痛(Patient-controlled subcutaneous analgesia,PCSA)用于晚期癌痛的可行性。选择晚期癌痛病例60例,随机分为3组,每组20例:Ⅰ组为口服吗啡组,Ⅱ组为芬太尼贴剂组,Ⅲ组为舒芬太尼PCSA组。分析治疗一周内视觉模拟评分(VAS),便秘、恶心呕吐、爆发性疼痛次数,病人家属满意度等五项数值差异。结果显示,三组在同样剂量递加的基础上,Ⅲ组VAS评分低于Ⅰ、Ⅱ组(P<0.05)。结果表明,舒芬太尼PCSA在晚期癌症镇痛效果好于口服吗啡和芬太尼贴剂,便秘、恶心呕吐、爆发性疼痛等不良事件发生率低,家属满意度高,值得临床推广。
The feasibility of PCSA （ Patient-controlled subcutaneous analgesia ） with sufentanil were investigated in the treatment of terminal cancer pain. 60 case of terminal cancer were selected and randomly divided into 3 groups with 20 patients in each group. Patients in Group I were given morphine orally, and group II were taken fentanyl through transdermal, and group III were treated by PCSA with sufentanil. VAS （Visual analogue scale ）, constipation, nausea ＆ vomiting, breakthrough pain, degree of satisfaction from patients＇ relatives were analyzed to assess the various treatment within a week. Based on the same bonus doses in three groups, VAS in group III was much lower than that in group I or group H. Compared to the treatment with morphine orally or transdermal fentanyl, PCSA with sufentanil behaved better in pain relief and caused lower adverse events such as less constipation, nausea and vomiting and breakthrough pain in terminal cancer.
出处
《莆田学院学报》
2013年第5期44-46,共3页
Journal of putian University
